
CryoLife, Inc. CRY
CryoLife, Inc. Gross Profit 2011-2026 | CRY
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit CryoLife, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 168 M | 183 M | 173 M | 129 M | 119 M | 90.7 M | 91.3 M | 90.4 M | 85 M | 75.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 183 M | 75.8 M | 120 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
532 M | $ 11.75 | -3.29 % | $ 1.76 B | ||
|
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | ||
|
Delcath Systems
DCTH
|
73.4 M | $ 8.98 | -1.32 % | $ 322 M | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
FONAR Corporation
FONR
|
42.4 M | $ 18.41 | 0.38 % | $ 121 M | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
Inogen
INGN
|
154 M | $ 6.32 | -2.02 % | $ 168 M | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.35 | - | $ 21.8 M | ||
|
IRadimed Corporation
IRMD
|
64.3 M | $ 100.97 | 1.78 % | $ 1.28 B | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
LivaNova PLC
LIVN
|
940 M | $ 62.4 | -1.33 % | $ 3.4 B | ||
|
LENSAR
LNSR
|
14.1 M | $ 5.56 | -8.4 % | $ 64 M | ||
|
AxoGen
AXGN
|
167 M | $ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
750 M | $ 36.56 | -0.19 % | $ 1.13 B | ||
|
Medtronic PLC
MDT
|
19.6 B | $ 86.58 | -0.68 % | $ 111 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
NanoVibronix
NAOV
|
1.51 M | - | - | $ 1.08 M | ||
|
Electromed
ELMD
|
50 M | $ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
InspireMD
NSPR
|
2.65 M | $ 1.79 | 3.47 % | $ 115 M | ||
|
Orthofix Medical
OFIX
|
566 M | $ 11.72 | -1.26 % | $ 464 M | ||
|
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
1.36 M | $ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
4.38 M | $ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | ||
|
Penumbra
PEN
|
942 M | $ 334.17 | -0.41 % | $ 13 B | ||
|
AdaptHealth Corp.
AHCO
|
89.3 M | $ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
26.9 M | $ 0.7 | -1.83 % | $ 29.3 M | ||
|
Insulet Corporation
PODD
|
1.94 B | $ 225.5 | -0.7 % | $ 15.9 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
-10.6 M | $ 2.4 | -1.64 % | $ 141 M | ||
|
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
26.6 M | $ 3.91 | 4.83 % | $ 146 M | ||
|
Quanterix Corporation
QTRX
|
65 M | $ 3.82 | -3.05 % | $ 163 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
46.8 M | $ 3.53 | -2.35 % | $ 53.7 K |